Literature DB >> 31257960

LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation.

Dianne Hartgerink1, Ans Swinnen1, David Roberge2, Alan Nichol2, Piotr Zygmanski3, Fang-Fang Yin4, François Deblois2, Coen Hurkmans5, Chin Loon Ong6, Anna Bruynzeel7, Ayal Aizer3, John Fiveash8, John Kirckpatrick3, Matthias Guckenberger9, Nicolaus Andratschke9, Dirk de Ruysscher1, Richard Popple8, Jaap Zindler1,10,11.   

Abstract

Introduction: Stereotactic radiosurgery (SRS) is a promising treatment option for patients with multiple brain metastases (BM). Recent technical advances have made LINAC based SRS a patient friendly technique, allowing for accurate patient positioning and a short treatment time. Since SRS is increasingly being used for patients with multiple BM, it remains essential that SRS be performed with the highest achievable quality in order to prevent unnecessary complications such as radionecrosis. The purpose of this article is to provide guidance for high-quality LINAC based SRS for patients with BM, with a focus on single isocenter non-coplanar volumetric modulated arc therapy (VMAT).
Methods: The article is based on a consensus statement by the study coordinators and medical physicists of four trials which investigated whether patients with multiple BM are better palliated with SRS instead of whole brain radiotherapy (WBRT): A European trial (NCT02353000), two American trials and a Canadian CCTG lead intergroup trial (CE.7). This manuscript summarizes the quality assurance measures concerning imaging, planning and delivery.
Results: To optimize the treatment, the interval between the planning-MRI (gadolinium contrast-enhanced, maximum slice thickness of 1.5 mm) and treatment should be kept as short as possible (< two weeks). The BM are contoured based on the planning-MRI, fused with the planning-CT. GTV-PTV margins are minimized or even avoided when possible. To maximize efficiency, the preferable technique is single isocenter (non-)coplanar VMAT, which delivers high doses to the target with maximal sparing of the organs at risk. The use of flattening filter free photon beams ensures a lower peripheral dose and shortens the treatment time. To bench mark SRS treatment plan quality, it is advisable to compare treatment plans between hospitals.
Conclusion: This paper provides guidance for quality assurance and optimization of treatment delivery for LINAC-based radiosurgery for patients with multiple BM.

Entities:  

Year:  2019        PMID: 31257960     DOI: 10.1080/0284186X.2019.1633016

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  13 in total

1.  Evaluation of the ability of the Brainlab Elements Cranial Distortion Correction algorithm to correct clinically relevant MRI distortions for cranial SRT.

Authors:  Paul Retif; Abdourahamane Djibo Sidikou; Christian Mathis; Romain Letellier; Emilie Verrecchia-Ramos; Rémi Dupres; Xavier Michel
Journal:  Strahlenther Onkol       Date:  2022-08-18       Impact factor: 4.033

2.  Impact of MRI timing on tumor volume and anatomic displacement for brain metastases undergoing stereotactic radiosurgery.

Authors:  Tugce Kutuk; Ranjini Tolakanahalli; Andre Williams; Martin C Tom; Jason D Vadhan; Haley Appel; Matthew D Hall; D Jay J Wieczorek; Stephen Davis; Michael W McDermott; Manmeet S Ahluwalia; Minesh P Mehta; Alonso N Gutierrez; Rupesh Kotecha
Journal:  Neurooncol Pract       Date:  2021-07-28

3.  Initial Experience With Single-Isocenter Radiosurgery to Target Multiple Brain Metastases Using an Automated Treatment Planning Software: Clinical Outcomes and Optimal Target Volume Margins Strategy.

Authors:  Giuseppe Minniti; Luca Capone; Filippo Alongi; Vanessa Figlia; Barbara Nardiello; Randa El Gawhary; Claudia Scaringi; Federico Bianciardi; Barbara Tolu; Piercarlo Gentile; Sergio Paolini
Journal:  Adv Radiat Oncol       Date:  2020-07-14

4.  Operation and calibration of the novel PTW 1600SRS detector for the verification of single isocenter stereotactic radiosurgery treatments of multiple small brain metastases.

Authors:  Esther Decabooter; Ans Cc Swinnen; Michel C Öllers; Fabian Göpfert; Frank Verhaegen
Journal:  Br J Radiol       Date:  2021-06-11       Impact factor: 3.629

5.  Prognostic impacts of extracranial metastasis on non-small cell lung cancer with brain metastasis: A retrospective study based on surveillance, epidemiology, and end results database.

Authors:  Miao Wang; Qiuji Wu; Jun Zhang; Guizhen Qin; Tian Yang; Yixin Liu; Xulong Wang; Boyu Zhang; Yongchang Wei
Journal:  Cancer Med       Date:  2020-12-15       Impact factor: 4.452

Review 6.  Brain metastases: the role of clinical imaging.

Authors:  Sophie H A E Derks; Astrid A M van der Veldt; Marion Smits
Journal:  Br J Radiol       Date:  2021-12-14       Impact factor: 3.039

Review 7.  Radiation Necrosis from Stereotactic Radiosurgery-How Do We Mitigate?

Authors:  Balamurugan A Vellayappan; Tresa McGranahan; Jerome Graber; Lynne Taylor; Vyshak Venur; Richard Ellenbogen; Andrew E Sloan; Kristin J Redmond; Matthew Foote; Samuel T Chao; John H Suh; Eric L Chang; Arjun Sahgal; Simon S Lo
Journal:  Curr Treat Options Oncol       Date:  2021-06-07

8.  The potential of an optical surface tracking system in non-coplanar single isocenter treatments of multiple brain metastases.

Authors:  Ans C C Swinnen; Michel C Öllers; Chin Loon Ong; Frank Verhaegen
Journal:  J Appl Clin Med Phys       Date:  2020-04-01       Impact factor: 2.102

Review 9.  Recent advanced in Surface Guided Radiation Therapy.

Authors:  P Freislederer; M Kügele; M Öllers; A Swinnen; T-O Sauer; C Bert; D Giantsoudi; S Corradini; V Batista
Journal:  Radiat Oncol       Date:  2020-07-31       Impact factor: 3.481

10.  Current status of intra-cranial stereotactic radiotherapy and stereotactic radiosurgery in Australia and New Zealand: key considerations from a workshop and surveys.

Authors:  Lauren Pudsey; Annette Haworth; Paul White; Zoe Moutrie; Benjamin Jonker; Matthew Foote; Joel Poder
Journal:  Phys Eng Sci Med       Date:  2022-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.